Skip to main content
. 2014 Jul 10;26(2):468–475. doi: 10.1681/ASN.2014030293

Figure 1.

Figure 1.

Effect of 6-week treatments with 75 mg o.d. slow-release indomethacin, 150 mg o.d. eplerenone, or 20 mg o.d. amiloride on plasma potassium concentration in patients with genetically proven GS type I. All datasets of valid periods of treatments for indomethacin (n=24), eplerenone (n=28), and amiloride (n=30) are used to connect plasma potassium values under treatment with corresponding pretreatment values. *p< 0.05; **p<0.01; ***p<0.001.